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Background: Measles virus (MeV) is monotypic, but genetic variation in the hemagglutinin H and nucleoprotein N
genes can be analyzed by molecular epidemiologic techniques and used to study virus transmission patterns. The
World Health Organization currently recognizes 8 clades (A-H) within which are 24 genotypes of MeV and one
provisional genotype, d11. Genotype B3 is clearly the endemic genotype in most of African continent where it is
widely distributed. We provide an update on the molecular characterization of wild-type MeVs that circulated in
Cameroon between 2010 and 2011.
Findings: Viral RNA was extracted directly from samples obtained from clinically diagnosed measles patients using
QIAamp viral RNA Mini Kit. Reverse transcription and PCR amplification of 634 nucleotides of the N gene was
performed using the SuperScript™ III One-Step. Sequence analysis of 450 of the 634 nucleotides using Clustal X 2.0
program for multiple alignments and Mega version 5 for phylogenic analysis indicated that all the viruses belonged
to genotype B3 with two distinct clusters. Twenty three (77%) belonged to subgroup B3.1 and the other 7 (23%)
belonged to B3.3 a recently described subtype. Circulation of cluster 3 was detected in the Far-North Region (5/7)
particularly along the Chad-Cameroon border in 2010 and later in Yaounde (2/7 in Biyem-assi Health District) the
capital city of Cameroon in 2011.
Conclusion: This study highlights the endemic circulation in Cameroon of MeV B3 subtype 1, which probably has
its source in the neighboring Nigeria, and the presence of the new subtype B3.3, suggesting a possible importation
from Northern Africa where it was first described between 2008 and 2009.
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Measles virus (MeV) is a negative-sense, single-stranded
RNA virus in the family Paramyxoviridae, genus
Morbillivirus. Infection with this virus typically causes
high fever, maculopapular rash, conjunctivitis, cough,
and coryza. MeV is monotypic, but genetic variation in
the hemagglutinin (H) and nucleoprotein (N) genes can
be analyzed by molecular epidemiologic techniques and
used to study virus transmission patterns [1]. The World
Health Organization (WHO) currently recognizes 8
clades (A-H) within which are 24 genotypes of MeV and
one provisional genotype, d11. Genotype B3 is clearly* Correspondence: demanou@pasteur-yaounde.org
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reproduction in any medium, provided the orthe endemic genotype in most of the African continent
where it is widely distributed [2].
In 1998, WHO implemented measles elimination
strategies and recommended that virological surveillance
be established in every country. Although this surveil-
lance is well established in all WHO regions, in some
areas it still not adequate [3]. The laboratory has two
main functions in measles surveillance: monitoring and
verifying virus transmission (confirmation of outbreaks
and identification of virus strains); and monitoring
susceptibility profile of the population [4]. In Cameroon,
distinct patterns of measles incidence are found in
two different areas. The three northern-most Regions
(Far-North, North and Adamaoua) experience major
epidemics every year. Seven southern Regions show
evidence of experiencing major epidemics every third year
[5]. Following coincident peaks in 2000–2001 in these tworal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.




Figure 1 Map of Cameroon showing the spatial (different Regions) and temporal (2010 and 2011) distribution of different subtypes of
measles virus genotype B3. An individual MeV case is represented either by a circle, a diamond or a triangle. Genotype B3 subtype 1 is
represented by double circles (year 2010) and black circles (year 2011). Genotype B3 subtype 3 is represented by black diamonds (year 2010) and
black triangles (year 2011).
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trywide, measles laboratory surveillance was established in
2001. This surveillance consisted mainly of serological con-
firmation of suspected cases. Following the WHO Measles
and Rubella Laboratory Network initiative to expand the
capacity of the national laboratories for virus isolation and
detection [6], a reverse-transcription polymerase chainreaction (RT-PCR) was set up in the Centre Pasteur of
Cameroon (CPC) National Reference Laboratory (NRL)
for measles in early 2011. Although genetic charac-
terization of wild-type viruses is an essential component
of laboratory-base surveillance, there are very few African
countries that use molecular tools for the surveillance of
measles. This paper provides an update on the molecular
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Cameroon between 2010 and 2011.
In the framework of measles case-based surveillance,
an outbreak is declared in a health district when the
laboratory has confirmed at least three consecutive cases
of measles with positive IgM antibodies. Therefore, all
clinically diagnosed cases are registered in a line listing
and only throat swabs samples are collected from 5 to
10 cases by the Expanded Program on Immunization
(EPI) surveillance team and sent to the NRL. From
February 2010 to July 2011, measles outbreaks were
registered in 37 out of 179 health districts in Cameroon
and throat swabs samples were collected from patients
with clinically diagnosed measles (Figure 1). Since the
throat swabs were collected as part of the Ministry ofTable 1 Characteristics of the 30 positive throat swabs sampl
patients with clinically diagnosed measles in Cameroon






























11V-5137 3.52 30/03/2011Health response to the outbreaks, through the standard
surveillance system as recommended by WHO and the
country EPI national standard operating procedures, no
authorization was required from the national ethics
committee. Viral RNA was extracted directly from these
samples using the commercial QIAamp viral RNA Mini
Kit (QIAGEN, Germany) according to the manufac-
turer’s instructions. Reverse transcription and PCR
amplification of the hypervariable 634 nucleotides of the
carboxy-terminal of the N gene was performed using
the SuperScript™ III One-Step RT-PCR System with
PlatinumW Taq High Fidelity (Invitrogen) and recently
described reverse MeV216 (50-TGGAGCTATGCCATGG
GAGT-30) and forward MeV214 (50-TAACAATGATGG
AGGGTAGG-30) primers [6]. From these amplicons, aes collected from February 2010 to July 2011 from















Maroua Urbain-Far North MVs/Maroua Urbain.CMR/47.10/
Maroua Urbain-Far North MVs/Maroua Urbain.CMR/48.10/3/
Maroua Urbain-Far North MVs/Maroua Urbain.CMR/47.10/2/
Maroua Urbain-Far North MVs/Maroua Urbain.CMR/49.10/4/
Guere-Far North MVs/Guere.CMR/8.10/
Koza-Far North MVs/Koza.CMR/24.11/
Maroua Rural-Far North MVs/Maroua Rural.CMR/28.11/
Maroua Urbain-Far North -
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assign a virus to a genotype) were obtained by using
BigDye terminator version 2.0 chemistry according to
the manufacturer’s protocol for both sense and antisense
strands on an automated ABI PRISM™ 3100 DNA
Sequencer (PerkinElmer, Applied Biosystems). Sequence
data were analyzed using Clustal X 2.0 program for
multiple alignments and Mega version 5 for phylogenetic
analysis. Dendrograms were drawn using the neighbour-
joining method. The sequences reported in this article
have been deposited into MeaNS (Measles Nucleotide
Surveillance), the database used to track measles se-
quence diversity and monitor elimination of virus
strains. MeV strains were named as designated by the
WHO [7] (Table 1, Figure 2).
Throat swabs collected from seventy two patients with


































































Figure 2 Phylogenetic analysis of the sequences of 30 strains of MeV
nucleotides coding for the nucleoprotein N gene. These trees were prepar
Bootstrap values are indicated (significant value >80%). The reference virus
Cameroonian sequences (in bold) are designated by their WHO name (in M
WHO reference sequences that are recommended for genotype identificat
MeV genotype B3 with the sequences of other genotype B3 viruses availabof the 30 variable region of the nucleoprotein (N) gene
were amplified from thirty of them. The characteristics
(date of collection, age, district and region of origin) of
the 30 patients are presented on Table 1. The 450
nucleotide sequences of these 30 patients were first
compared to the WHO reference sequences that are
recommended for genotype identification. All the se-
quences clustered with NY.USA 94 and Ibadan.NIE 97
[GenBank:AJ232203.1], the reference sequences for
genotype B3 (Figure 2a) which is clearly the endemic
genotype in most of the African continent with the
exception of the North African countries in the Eastern
Mediterranean Region [3]. Since genotype B3 has been
divided into 3 clusters [8], the sequences from the 30
Cameroonian MeVs were compared to the sequences of
other genotype B3 viruses that were available in the
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from Cameroon. The trees were constructed based on the 450
ed using Mega version 5 software and the neighbour-joining method.
es are designated by their GenBank accession numbers. The
eaNS): The comparison of the Cameroonian MeV strains with the
ion is represented on graph 2a. The comparison of the Cameroonian
le on GenBank is shown on graph 2b.
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Twenty three (77%) belonged to subgroup B3.1 and the
other 7 (23%) belonged to B3.3. Although cluster 1 has
previously been isolated in Central (Cameroon and
Central African Republic), West (Ghana and Nigeria)
and East (Kenya and Tanzania) African countries [9-11],
cluster 2, which was not found during our study appears
to be more limited to Western Africa [12]. Nevertheless,
cluster 3, which was recently and for the first time,
described to have circulated during 2008 and 2009 in
Northern Africa (Tunisia and Libya) [8] is also present
in Cameroon. This is to our knowledge, the second
report of this new subtype of genotype B3 in Africa, and
its first description in Central Africa. Furthermore, the
Cameroonian sequences were also compared to the
other B3 sequences in MeaNS (data not shown). The
results of this blast search show that 77% (corresponding
to the above sub-group B3.1) of the sequences were
probably imported from the neighbouring Nigeria as
they display more than 98% identity with the strains that
circulated in Nigeria between 2010 and 2011. For the
remaining 23% (B3.3), 5 of them (one from Goulfey,
Kousseri and Guere and two from Biyem-Assi Health
Districts) showed a 100% identity between themselves
and are 99.5% identical to a strain isolated in Madrid
(Spain) in 2008 from a patient with history of recent
travel to Equatorial Guinea. One strain from Guere
Health District exhibits a 100% identity with the 6
strains isolated in Tunisia and Libya in 2008–2009 and
described as cluster 3 [8].
Circulation of cluster 3 was detected in the Far-North
Region (5/7) particularly along the Chad-Cameroon
border (Goulfey, Kousseri and Guere Health Districts) in
2010 and later in Yaounde (2/7 in Biyem-assi Health
District) the capital city of Cameroon in 2011 (Figure 1)
suggesting a probably importation of this subtype from
Libya (in the Northern Africa) through Chad. It has been
established after a five-year study that there are two
distinct patterns of measles incidence in two different
areas in Cameroon [5]. The three northern-most Regions
experience major epidemics every year. Seven southern
Regions show evidence of experiencing major epidemics
every third year. The same patterns have been observed
during the last decade and the reasons of these differences
are not very clear since Cameroon is among the 31 coun-
tries with measles-containing vaccines coverage of 50-79%
for infants (Vaccination coverage from WHO/UNICEF
estimates 1980–2005, August 2006). Investigations should
therefore be sustained to monitor the circulation of the
MeV genotype B3 cluster 3 in the upcoming years in
Cameroon (and in Central Africa) in order to assess its
implication in multiple outbreaks faced every year espe-
cially in 2012 which extended to almost the entire country
(8/10 Regions affected).In conclusion, this study describes molecular charac-
teristics of clade B measles viruses circulating in
Cameroon with reports of recent isolates from 2010 to
2011. It also highlights the endemic circulation of MeV
B3 subtype 1, which probably has its source in the
neighbouring Nigeria, and the presence of the new
subtype (B3.3), suggesting a possible importation from
Northern Africa where it was first described between
2008 and 2009.
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